ASH Conference Coverage
Filter News By:

Featured Conference News

ASH20: ASCEMBL Trials Shows Asciminib Effectiveness as Third-Line Treatment for CML

December 08 2020 - The STAMP inhibitor asciminib appears safe and effective as third-line treatment for patients with chronic myeloid leukemia (CML) in chronic phase, according to findings from the phase 3 ASCEMBL trial.

ASH20: Genetic Mutations Could Help Predict Cancer Symptoms Decades in Advance

December 08 2020 - Using whole genome sequencing, researchers have traced the genetic origins of myeloproliferative neoplasms to early childhood, and in some cases all the way back to the time in utero.

ASH20: ZUMA-12 Trial Shows Initial Success in Front-Line CAR T-Cell Treatment For Aggressive Lymphoma

December 07 2020 - Axicabtagene ciloleucel (axi-cel) appeared effective and well tolerated as first-line therapy for high-risk large B-cell lymphoma in the phase 2 ZUMA-12 study, which was presented at the annual meeting of the American Society of Hematology.

ASH20: Chemo-Free Treatment Shows Promise in Elderly, Unfit Patients With Untreated DLBCL

December 07 2020 - Single-agent mosunetuzumab appeared effective and well tolerated as first-line treatment for elderly and unfit patients with diffuse large B-cell lymphoma (DLBCL) in an early-phase trial, according to findings presented at the annual meeting of the American Society of Hematology.

ASH20: Final Analysis From iNNOVATE Favors Ibrutinib-Rituximab Combo in WM

December 06 2020 - A final analysis of the phase 3 iNNOVATE trial found deepening responses and continued safety for the combination of ibrutinib and rituximab in patients with Waldenström’s macroglobulinemia, according to findings presented at the annual meeting of the American Society of Hematology.

ASH20: Trial Points to Blinatumomab as Standard of Care For First Relapse BCP-ALL

December 06 2020 - Blinatumomab monotherapy before allogeneic hematopoietic stem cell transplant could become a new standard of care for children with high-risk, first-relapse B-cell precursor acute lymphoblastic leukemia (BCP-ALL), findings presented at the annual meeting of the American Society of Hematology suggest.

ASH20: Preclinical Study Shows Promise of Off-the-Shelf T Cells in COVID-19

December 06 2020 - Building on their knowledge in developing cellular therapies, researchers at Baylor College of Medicine have created a bank SARS-CoV-2-specific T-cells that could someday be used to treat patients with severe COVID-19 infection. The findings, which come from a preclinical feasibility study, were reported at the annual meeting of the American Society of Hematology.

ASH20: Younger Black AML Patients Have Worse Outcomes With Same Care

December 05 2020 - Black patients with acute myeloid leukemia (AML) who are under age 60 had worse outcomes than their white counterparts, even when they received the same care, according to findings reported at the annual meeting of the American Society of Hematology.

ASH20: Tranexamic Acid Fails to Prevent Bleeding in Patients with Hematologic Malignancy

December 05 2020 - Tranexamic acid was not effective in preventing bleeding when added to routine transfusion therapy in patients undergoing treatment for hematologic malignancy, according to findings presented at the annual meeting of the American Society of Hematology.

ASH20: Zuma-5 Analysis Shows Potential For CAR T-cell Treatment in Indolent Lymphomas

December 05 2020 - The anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel achieved a complete response rate of more than 75% among patients with relapsed/refractory indolent non-Hodgkin lymphomas, according to findings presented at the annual meeting of the American Society of Hematology.

Featured News
View all
More News
(DocWire News) Dec 21, 2020 - The all-virtual 62nd ASH Annual Meeting & Exposition highlighted some of the newest data about Venclexta.
(MedPage Today) Dec 11, 2020 - Bispecific antibodies targeting CD20 and CD3 led to response rates as high as 90% in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who had received CAR T-cell therapy,...
(Fred Hutch) Dec 10, 2020 - The pandemic loomed large over ASH 2020, and not just because of its impact on the format.
(Pharmaphorum.com [UK]) Dec 9, 2020 - Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, according to new figures unveiled this weekend.
(Curetoday.com) Dec 8, 2020 - The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.
(Medscape Medical News) Dec 8, 2020 - Duvelisib is demonstrating encouraging activity and manageable toxicities among patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) in a phase 2 trial, an investigator said.
(DocWire News) Dec 9, 2020 - Ajai Chari, MD, PhD, of Mount Sinai Medical Center in New York, NY, discusses findings from a phase I study of the novel agent talquetamab, a first-in-class bispecific antibody that binds to GPRC5D and CD3, for...
(Medscape Medical News) Dec 7, 2020 - New findings show that ruxolitinib (Jakafi) was superior to standard therapy in reducing symptoms of cGVHD in the second-line setting, and the results are potentially practice changing.
(Curetoday.com) Dec 8, 2020 - This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.
(OBR) Dec 8, 2020 - Using whole genome sequencing, researchers have traced the genetic origins of myeloproliferative neoplasms to early childhood, and in some cases all the way back to the time in utero. The findings, which were...

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?… https://t.co/MwVpuqeCFN

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj